Abstract
Background:
Müllerian adenocarcinoma is a very rare and aggressive cancer originating from the uterus and ovary, affecting almost exclusively women. Few cases of extragenital Müllerian adenocarcinomas have been reported, in various locations ranging from pelvic peritoneum to diaphragm peritoneum. Very few cases of Müllerian adenocarcinoma in men have been reported in scientific literature, usually localized in the prostate seminal vesicles and testicles, associated to a very poor prognosis.
Case summary:
In this paper, we describe the unique clinical case of a man affected by advanced Müllerian adenocarcinoma on the left side of the pelvis, treated with a combination of surgery, chemotherapy, and radiotherapy, with a long follow-up. Patient survival was exceptional (almost 15 years from diagnosis), and the patient experienced a good quality of life during the numerous treatments. To the best of our knowledge, this is the first case report regarding a Müllerian adenocarcinoma of the pelvis in a man treated with a multimodal therapy approach and with a very long follow-up and very long survival. In consideration of the embryological origin of ovaries from Müllerian ducts and the absence of specific guidelines for standard treatment for this tumor, the patient was treated as if he had ovarian cancer, with optimal results.
Conclusions:
The management of this patient with modern available lines of chemotherapy classically employed in ovarian cancer plus radiotherapy combined with several bouts of cytoreductive surgery could explain this long survival.
Introduction
Müllerian adenocarcinoma is a very rare and aggressive cancer originating from the uterus and ovary (), predominantly affecting women. Its rarity is clearly related to the absence of a female embryonic component in men. It is well known that there is an undifferentiated gonad in the initial stages of embryogenesis. Therefore, if there is a differentiation in the male direction, the female embryonic component goes into complete involution. Conversely, if there is a differentiation in the female direction, the male gonad goes into complete regression. The pathogenetic hypothesis of the Müllerian tumor in humans refers to clusters of female Müllerian cells that have not completely regressed. Müllerian tumor cells could be created from these clusters.
Few cases of extragenital Müllerian adenocarcinomas have been reported, in various locations ranging from pelvic peritoneum to diaphragm peritoneum (). Very few cases of Müllerian adenocarcinoma in men have been reported in scientific literature, usually localized in the prostate seminal vesicles and testicles, associated to a very poor prognosis (–).
In this paper, we describe the unique clinical case of a man aged between 60 and 80 years and affected by advanced Müllerian adenocarcinoma on the left side of the pelvis, treated with a combination of surgery, chemotherapy, and radiotherapy, with a long follow-up (, ).
Patient survival was exceptional (almost 15 years from diagnosis), and the patient experienced a good quality of life (QoL) during the numerous treatments. To the best of our knowledge, this is the first case report regarding a Müllerian adenocarcinoma of the pelvis in a man treated with a multimodal therapy approach (surgery plus chemotherapy plus radiotherapy) with a very long follow-up and very long survival (, ).
The therapeutic strategy employed for this patient, including chemotherapy and surgical treatments, might represent an important reference for the treatment of these very rare and aggressive tumors in men.
Case presentation
Initial presentation: A male patient aged between 60 and 80 years presented with a weight of 70 kg, a height of 175 cm, and a BMI of 22.86, suffering from a left inguinal hernia that was never surgically treated.
In the first half of 2005, he was hospitalized at the Surgery Unit of Di Venere Hospital of Bari (Italy) for resection surgery of the sigma and placement of a ureteral stent because of an intestinal occlusion and hydronephrosis of the left kidney due to a mass of 4 cm at the left side of pelvis with infiltration of the left ureter and the sigma. He was married and a father of children. He was normally virilized and had normal genitals and mild gynecomastia.
Histopathological findings: The first histopathological examination was not conclusive, and a second histopathological opinion has been performed at IRCCS Istituto Tumori Giovanni Paolo II of Bari (Italy). Upon examination using the hematoxylin and eosin technique, epitheliomorphic cancer was diagnosed. It consisted of adeno-papillary architecture with cells expressing a ciliated border and with a rich psammomatous stromal component (Figures 1A–C) ().
Figure 1
Immunohistochemical examination demonstrated a strong nuclear brown immunoreactivity for estrogen receptors (diaminobenzidine chromogen) with focal and limited immunoreactivity for progesterone receptors (Figure 2A).
Figure 2
Finally, immunohistochemistry also showed a strong membrane immunoreactivity for Wilms’ Tumor One (WT1), a typical marker of ovarian cancer. WT1, located on chromosome 11p13, is a tumor suppressor gene involved in Wilms’ tumor development. Normally, its expression is limited to the kidney, gonads, spleen, hematopoietic precursors, and fetal mesothelium. Furthermore, WT1 also exhibits oncogenic activity, and its overexpression has been well demonstrated in ovarian cancer; thus, WT1 immunohistochemical detection is considered as a diagnostic marker of ovarian cancer (Figure 2B) ().
Diagnosis: On these bases, the diagnosis of a very rare papillary serous adenocarcinoma originating from Müllerian ducts residues was formulated in this patient.
Treatment
The patient was offered adjuvant chemotherapy in accordance with the treatment strategy for ovarian cancer. The patient has undergone adjuvant chemotherapy with carboplatin (AUC 5) plus paclitaxel (175 mg/m2) every 3 weeks for six cycles at the Oncology Unit of IRCCS De Bellis of Castellana Grotte (Italy) (). Subsequently, follow-up was started including Ca125 serum dosage, thorax–abdomen CT scan every 6 months, and positron emission tomography/computed tomography (PET/CT) scan every 1 year.
Outcome and follow-up
In the first half of 2011, a radiological evaluation put in evidence a pelvic recurrence of the disease. Total body PET/CT showed radiopharmaceutical hyperaccumulation in the left iliac region [maximum Standard Uptake Value (mSUV) of 9.9], presacral/coccygeal area (mSUV of 4.2), peri-bladder region (mSUV of 8.9), and at the posterior wall of the rectum (mSUV of 3.2). Therefore, he was admitted to the Surgery Unit of IRCCS Istituto Tumori Giovanni Paolo II of Bari (Italy) for resection of pelvic disease recurrence. In consideration of tumor platinum sensibility (6 years of disease-free survival from the last administered cycle of platinum-based chemotherapy), the patient received a re-challenge of the adjuvant therapy with carboplatin and paclitaxel at the Integrative Medical Oncology Unit of IRCCS Istituto Tumori Giovanni Paolo II of Bari (Italy).
One year later, a follow-up CT scan shows a left obturator and peri-bladder neoformation of 4 cm. PET/CT documented radiopharmaceutical hyperaccumulation at the left obturator (mSUV of 7.7) (Figure 3). These lesions were also evident at CT of co-registration.
Figure 3
In the second half of 2013, 15 cycles of radiotherapy at IRCCS Istituto Tumori Giovanni Paolo II of Bari (Italy) are carried out on pelvic recurrence (200 cGy for each day for 3 weeks, 5 days a week) in the left obturator region to reduce painful symptoms localized in the left pelvic region and hip. The radiological and laboratory follow-up exams showed the stability of disease (SD) until December 2013. In consideration of tumor platinum sensibility, 2 years of progression-free survival (PFS) from the last administered cycle of platinum-based chemotherapy, the patient again received chemotherapy with carboplatin and paclitaxel at the Integrative Medical Oncology Unit of IRCCS Istituto Tumori Giovanni Paolo II of Bari (Italy). The patient experienced a good QoL and a PFS of 3 years.
In the first half of 2017, the PET/CT scan showed a progression of disease (PD) consisting of increased uptake of radiopharmaceuticals (Figure 4a). At the same time, the co-registration CT scan documented the volumetric increase of the tumoral mass, from 4 to 6 cm, at the left perivesical site of the pelvis. Please note the characteristic psammomatous bodies in the lesion (Figure 4b).
Figure 4
Therefore, the second line of chemotherapy with carboplatin AUC 3.5 mg/mL per minute plus gemcitabine 800 mg/m2 was administered at the Integrative Medical Oncology Unit of IRCCS Istituto Tumori Giovanni Paolo II of Bari (Italy). Thus, the patient experienced a PFS of 3.5 years. In June 2019, PET/CT showed PD due to an increased radiopharmaceutical uptake at the target lesion (mSUV of 12.5) (Figures 4c, d).
On this basis, chemotherapy with gemcitabine 800 mg/m2 for 12 weekly cycles was administered until January 2020 for further PD.
Unfortunately, the patient died in 2020 because of a septic shock.
Discussion
The tumor that originates from residues of Müllerian ducts is very rare in women and exceptional in men, with a poor prognosis. Because of its extreme rarity, the diagnosis is not often considered, and no guidelines establishing any standard treatment are available.
In this case report, we described the clinical history of a male patient affected by a Müllerian tumor with a 15-year survival from diagnosis to death, thanks to a treatment strategy including surgery, several chemotherapy lines, and radiotherapy (Table 1) (, ). It should be noted that the WT1 antibody was employed for histopathological examination. The strong membrane immunoreactivity to WT1 antibody suggests its possible use as a marker for diagnosis ().
Table 1
| Date | Treatment | Response |
|---|---|---|
| 2005 | Surgical resection of sigmoid colon and ureteral stent placement due to pelvic mass with ureter and sigmoid infiltration, and adjuvant chemotherapy: Carboplatin (AUC 5) + paclitaxel (175 mg/m²) × six cycles | CR |
| 2011 | Surgery for pelvic recurrence and subsequent chemotherapy with carboplatin + paclitaxel | PR |
| 2013 | Pelvic radiotherapy (15 cycles, 200 cGy/day × 3 weeks) for local recurrence (left obturator, peri-bladder) and re-challenge with carboplatin + paclitaxel | PD |
| 2017 | Second-line chemotherapy: carboplatin AUC 3.5 + gemcitabine 800 mg/m², because of progression on PET/CT (lesion growth and increased uptake) | PD |
| 2019 | Gemcitabine 800 mg/m² × 12 weekly cycles (progression on PET/CT) | PD |
| 2020 | Death due to septic shock | – |
Chronological summary of treatments and outcomes.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
In consideration of the embryological origin of ovaries from Müllerian ducts and the absence of specific guidelines for standard treatment for this tumor, the patient was treated as if he was affected by ovarian cancer, with optimal results. Our experience also suggests the Müllerian tumor sensitivity to radiotherapy.
Interestingly, the survival of our patient was impressive, especially if compared to other cases (–). The possible explanation for this favorable prognosis could be related to the low production of estrogens in men as compared to women; this hypothesis could be supported by the absence of the persistent Müllerian duct syndrome in our patient, although the tumor expressed estrogen receptors.
Based on our literature search, there do not appear to be any studies that have correlated estrogen levels with the prognosis of male Müllerian carcinoma. We found only 3 case reports of male Müllerian carcinoma with a low survival rate (Table 2). Therefore, the rarity of the event may justify this lack of data. However, some studies have hypothesized that high estrogen levels may be related to the development of ovarian cancer. In addition, it is known that some studies indicate that hormonal therapies that inhibit the estrogen–estrogen receptor axis (e.g., tamoxifen) could be a therapeutic approach in female ovarian cancer ().
Table 2
| N | Title | Authors | Source | Year | Patient | Therapy | Overall Survival |
|---|---|---|---|---|---|---|---|
| 1 | Papillary serous carcinoma of the peritoneum in a man: a case report | Shah IA, Jayram L, Gani OS, Fox IS, Stanley TM. | Cancer | 1998 | 74 years old man | cisplatin (HIPEC) and paclitaxel (iv) | 3 mounth |
| 2 | Primary papillary serous carcinoma of the peritoneum in a man | Shmueli E, Leider-Trejo L, Schwartz I, Aderka D, Inbar M. | Ann Oncol | 2001 | 53 years old man | cisplatin and 5-fluorouracil (iv) | 2 mounth |
| 3 | Photodynamic detection and management of intraperitoneal spreading of primary peritoneal papillary serous carcinoma in a man: report of a case | Canbay E, Ishibashi H, Sako S, Kitai T, Nishino E, Hirano M, Mizumoto A, Endo Y, Ogura S, Yonemura Y. | Surg Today | 2014 | 63 years old man | cytoreductive surgery and docetaxel (HIPEC) and docetaxel (LPS) and cisplatin (iv) | 18 mounths |
Comparable cases.
In addition, the management of this patient with modern available lines of chemotherapy classically employed in ovarian cancer, plus radiotherapy combined with several bouts of cytoreductive surgery, could explain this exceptional long survival (–).
Finally, the data reported in this paper might be useful in defining the diagnosis of Mullerian tumor for the suspected clinical cases and the management of these patients.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
Ethics statement
It is a single case report, the therapeutic pathways are approved and currently used in clinical practice and the data have been completely anonymized. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and institutional requirements because the patient is dead. All data has been completely anonymized. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article because the patient is dead. All data has been completely anonymized.
Author contributions
GR: Conceptualization, Methodology, Supervision, Validation, Writing – original draft, Writing – review & editing. MP: Data curation, Supervision, Writing – review & editing. AM: Supervision, Writing – review & editing. AD: Writing – review & editing. CF: Writing – review & editing. AZ: Conceptualization, Data curation, Methodology, Supervision, Writing – review & editing. MA: Writing – review & editing. CL: Writing – review & editing. GM: Investigation, Methodology, Supervision, Writing – original draft, Writing – review & editing. SB: Data curation, Methodology, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. This work was supported by the Italian Ministry of Health, Fondi Ricerca Corrente – Deliberazione n.91/2024.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
CobbLPGaillardSWangYShihIeMSecordAA. Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecol Oncol Res Pract. (2015) 2:1. doi: 10.1186/s40661-015-0008-z
2
GuellilAJabiRMabroukMYBouzayanLMerhoumADel GalloGet al. Primary peritoneal high-grade serous carcinoma in a man: A case report. Ann Med Surg. (2022) 77:103605. doi: 10.1016/j.amsu.2022.103605
3
AnchalaPRDhirRParwaniAVZyngerDL. Immunohistochemical profile of paratesticular serous papillary adenocarcinoma and tunica vaginalis facilitates distinction from Malignant mesothelioma. Int J Surg Pathol. (2011) 19:692–8. doi: 10.1177/1066896909337504
4
ZeighamiSSoltaniMKhajehFAriafarANaghdi-SedehN. Testicular papillary serous carcinoma of ovarian type, a rare case report, however an important timely diagnostic issue. Urol Case Rep. (2020) 33:101301. doi: 10.1016/j.eucr.2020.101301
5
NeuhausenSLShaniHBokerLKSteeleLSilvermanBGOttiniLet al. Primary peritoneal serous carcinoma in men: A rare and non-BRCA-associated entity. Anticancer Res. (2017) 37:3069–72. doi: 10.21873/anticanres.11662
6
LoizziVCicinelliESantamariaFMurgiaFMinicucciVRestaLet al. BRCAmut and “founder effect”: a prospective study in a single academic institution. Oncotarget. (2018) 9:22353–22358. doi: 10.18632/oncotarget.24959
7
PusiolTZorziMGMorichettiDPiscioliIScialpiM. Peritoneal Malignant psammomatous mesothelioma. World J Oncol. (2010) 1:179–181. doi: 10.4103/0377-4929.77409
8
CarterJHDeddensJAMuellerGLewisTGDooleyMKRobillardMCet al. Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer. Br J Cancer. (2018) 119:462–70. doi: 10.1038/s41416-018-0191-x
9
LoizziVRanieriGLaforgiaMGadaletaCDGarganoGKardhashiAet al. PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective. Oncol Lett. (2020) 20:90. doi: 10.3892/ol.2020.11951
10
CanbayEIshibashiHSakoSKitaiTNishinoEHiranoMet al. Photodynamic detection and management of intraperitoneal spreading of primary peritoneal papillary serous carcinoma in a man: report of a case. Surg Today. (2014) 44:373–7. doi: 10.1007/s00595-013-0500-1
11
ShahIAJayramLGaniOSFoxISStanleyTM. Papillary serous carcinoma of the peritoneum in a man: a case report. Cancer. (1998) 82(5):860–6. doi: 10.1002/(sici)1097-0142(19980301)82:5<860::aid-cncr9>3.0.co;2-n
12
ShmueliELeider-TrejoLSchwartzIAderkaDInbarM. Primary papillary serous carcinoma of the peritoneum in a man. Ann Oncol. (2001) 12(4):563–7. doi: 10.1023/a:1011115930434
13
KoziełMJPiastowska-CiesielskaAW. Estrogens, estrogen receptors and tumor microenvironment in ovarian cancer. Int J Mol Sci. (2023) 24(19):14673. doi: 10.3390/ijms241914673
14
De NolaRMengaACastegnaALoizziVRanieriGCicinelliEet al. The crowded crosstalk between cancer cells and stromal microenvironment in gynecological Malignancies: biological pathways and therapeutic implication. Int J Mol Sci. (2019) 20:2401. doi: 10.3390/ijms20102401
15
NaniwadekarMRDesaiSRRanadeRGKanetkarSR. Extra genital heterologous Malignant mixed mullerian tumor of primary peritoneal origin. Indian J Pathol Microbiol. (2009) 52:88–90. doi: 10.4103/0377-4929.44976
16
LafaceCRanieriGMaselliFMAmbrogioFFotiCAmmendolaMet al. Immunotherapy and the combination with targeted therapies for advanced hepatocellular carcinoma. Cancers. (2023) 15:654. doi: 10.3390/cancers15030654
Summary
Keywords
Müllerian adenocarcinoma in male, pelvis, multimodal oncology therapy, long survival, case report
Citation
Ranieri G, Porcelli M, Mastrorosa A, Di Palo A, Ferrari C, Zito AF, Ammendola M, Laface C, Mastrandrea G and Berardone S (2025) Long-term survival in a male patient with Müllerian adenocarcinoma of the pelvis: a 15-year case report. Front. Oncol. 15:1610783. doi: 10.3389/fonc.2025.1610783
Received
12 April 2025
Accepted
03 June 2025
Published
02 September 2025
Volume
15 - 2025
Edited by
Alex Mutombo Baleka, University of Kinshasa, Democratic Republic of Congo
Reviewed by
Olugbenga Akindele Silas, University of Jos, Nigeria
Zuhal Hamd, Princess Nourah bint Abdulrahman University, Saudi Arabia
Updates
Copyright
© 2025 Ranieri, Porcelli, Mastrorosa, Di Palo, Ferrari, Zito, Ammendola, Laface, Mastrandrea and Berardone.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Giovanni Mastrandrea, g.mastrandrea@oncologico.bari.it
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.